Trials: Myeloma

You are here:

Find a Clinical Trial
Myeloma

A Prospective Observational Study of Patients with Monoclonal Gammopathy (MGUS) and Asymptomatic Mulitple Myeloma

October 30, 2025

Evaluation of a flow cytometry assay measuring BCMA CAR-T cells and T cell characterization in treated patients

November 24, 2025

NCT04634552 – A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

November 24, 2025

NCT04771078 – Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel that is Nonconforming for Commercial Release

October 30, 2025

NCT05346835 – Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

October 30, 2025

NCT05561387 – S2209, A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance

October 30, 2025

NCT05561387 – S2209, A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance

October 30, 2025

NCT05675449 – A Phase 1B, Open-label Study of Elranatamab in Combination with Carfilzomib Plus Dexamethasone and Elranatamab in Combination with PF-07901801 in Participants with Relapsed Refractory Multiple Myeloma

October 30, 2025

NCT05932680 – Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed Refractory Multiple Myeloma

October 30, 2025

NCT06313502 – High dose ascorbic acid (HDAA) in patients with plasma cell disorders

January 8, 2026

NCT06313502 – High dose ascorbic acid (HDAA) in patients with plasma cell disorders

January 8, 2026